Welcome to our dedicated page for Kala Pharmaceuticals SEC filings (Ticker: KALA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KALA BIO, Inc. SEC filings document the company's common stock, capital structure, governance, material agreements, listing status, and strategic transition from a clinical-stage biopharmaceutical issuer toward a dual biotech and AI infrastructure model. Recent Form 8-K disclosures cover the 1-for-50 reverse stock split, amendments to the certificate of incorporation, Nasdaq minimum-bid-price matters, and executive and board changes.
The filings also record material contracts and financing arrangements, including the Researgency platform development and exclusive license agreement, shelf-registration activity, at-the-market offering documents, and registered direct offering disclosures. Periodic and notice filings address annual-report timing, operating and financial reporting, risk factors, and the documentation needed for the company's evolving biologics pipeline and AI platform strategy.
KALA BIO entered a Platform Development and Exclusive License Agreement with Younet AI, securing a worldwide exclusive license to the Researgency biomedical AI research platform for an initial 12‑month term, with options for successive one‑year renewals. KALA will pay up to $530,000 in cash during the initial term and issue 5,000,000 shares of common stock to Younet, with each renewal triggering an additional $250,000 in cash and 5,000,000 shares. Younet agreed not to sell more than 3% of daily trading volume in its shares on any trading day, except for certain block trades. KALA also obtained an irrevocable option to acquire all of Younet’s equity or substantially all of its assets for $55,000,000. The company plans to use Researgency first on its own datasets, then to build an on‑premises AI infrastructure platform offered to biotech and pharmaceutical clients on a subscription basis.
KALA BIO, Inc. reported that on February 16, 2026, director David Lazar resigned from the company’s Board of Directors, effective the same day. The company stated that Mr. Lazar’s resignation was not related to any disagreement with KALA BIO regarding its operations, policies, or practices. The filing is a governance update and does not describe any accompanying strategic or financial changes.
KALA BIO, Inc. is registering up to 241,435,910 shares of common stock for resale by existing stockholders, including 238,335,910 shares issued or issuable upon conversion of preferred stock plus shares issued under settlement agreements with LifeSci Capital and Baker Brothers funds. This is a resale registration only, so KALA will not receive proceeds from any share sales, while it will cover registration expenses and selling stockholders will pay any selling commissions.
The shares were largely created through a $6.0 million private placement of Series AA and Series AAA preferred stock and through equity-based settlements of advisory and participation-rights disputes. As of February 4, 2026, 911,330,225 common shares were outstanding.
KALA highlights significant listing risk: Nasdaq has notified the company that it is below the $35 million market value of listed securities requirement, with a compliance deadline of May 11, 2026, and below the $1.00 minimum bid price requirement, with a compliance period through July 20, 2026. Failure to regain compliance could lead to delisting, reduced liquidity, penny-stock status and greater difficulty raising capital.
Baker Bros. Advisors and affiliates report a 9.99% beneficial stake in KALA BIO, Inc. They disclose beneficial ownership of 2,890,055 shares of common stock, including 1,086,000 shares issuable upon conversion of 10,860 shares of Series G non-voting convertible preferred stock.
The ownership calculation uses 27,849,725 KALA common shares outstanding as of December 31, 2025, plus the Series G convertible shares. The filing notes a “Beneficial Ownership Limitation” that generally caps the group’s ownership at 9.99% of KALA’s outstanding common stock for conversion purposes.
The preferred stock series (E, F, G and H) are each convertible into common stock on a 1‑for‑100 basis without additional consideration, but only to the extent conversion does not breach the ownership cap. The funds may adjust this cap up to 19.99%, with any increase becoming effective on the 61st day after notice to KALA.
KALA BIO, Inc. files a resale registration covering up to 241,435,910 shares of common stock for existing stockholders. The shares include 238,335,910 shares from preferred stock conversions, 2,200,000 shares issued to LifeSci Capital LLC, and 900,000 settlement shares issued to Baker Brothers entities.
All shares may be sold from time to time by the selling stockholders, and KALA will not receive any proceeds from these sales, though it will pay registration expenses. As context, 911,330,225 shares of common stock were outstanding as of February 4, 2026. The filing also highlights Nasdaq notices that KALA is currently below market‑value and minimum bid‑price listing requirements, creating a risk of potential delisting if compliance is not regained.
KALA BIO director Brendan P. Purdy filed an initial ownership report stating he currently holds no company securities. The Form 3 identifies him as a director of KALA BIO, Inc. and confirms that no non-derivative or derivative securities are beneficially owned as of the reported event date.
The filing also notes that a power of attorney authorizes Avraham Minkowitz to sign and submit the report on Purdy’s behalf.
KALA BIO, Inc. director Hillel D. Posen filed an initial statement of beneficial ownership as a reporting person. The filing states that no securities of KALA BIO are beneficially owned. It also records that Posen granted a power of attorney authorizing Avraham Minkowitz to sign and file the report on his behalf.
KALA BIO, Inc. filed an initial ownership report (Form 3) for Avraham Minkowitz, who is both a director and the Chief Executive Officer. As of the event date of 01/30/2026, the filing states that no securities are beneficially owned, including no derivative securities positions.
KALA BIO director reports no stock ownership in initial filing
Director Colman Yonatan C. filed an initial ownership report with KALA BIO, Inc. stating that no securities are beneficially owned. The form also notes that a Power of Attorney authorizes Avraham Minkowitz to sign and submit the filing on the director’s behalf.
KALA BIO, Inc. director Chaim D. Berger filed an initial insider ownership report on Form 3. The filing states that, as of the event date of 01/30/2026, he beneficially owns no securities of KALA BIO. The form was signed and submitted by attorney-in-fact Avraham Minkowitz under a power of attorney attached as Exhibit 24.